4 Results for "

MCL-1/BCL-2-IN-2

" in MedChemExpress (MCE) Product Catalog:
Products (4)

4 Results for "MCL-1/BCL-2-IN-2" in MCE Product Catalog:

Cat. No.: HY-129700
CAS No.: 2163793-44-8
Purity:  99.05%
Target:  

Bcl-2 Family

Research Areas:  

Cancer

MCL-1/BCL-2-IN-2 is a Mcl-1 and Bcl-2 inhibitor with IC50 values of 5.4 and 7.66 μM. MCL-1/BCL-2-IN-2 is applicable to the research of Mcl-1-dependent cancers .
loading...
    loading...
Cat. No.: HY-132307
CAS No.: 2598978-56-2
Purity:  98.40%
Target:  

Bcl-2 Family Apoptosis

Research Areas:  

Cancer

Mcl-1 inhibitor 6 is an orally active, selective myeloid cell leukemia 1 (Mcl-1) protein inhibitor with a Kd of 0.23 nM and a Ki of 0.02 μM. Mcl-1 inhibitor 6 possesses superior selectivity over other Bcl-2 family members (Bcl-2, Bcl2A1, Bcl-xL, and Bcl-w, Kd>10 μM). Mcl-1 inhibitor 6 is a potent antitumor agent .
loading...
    loading...
Cat. No.: HY-129681
CAS No.: 2493256-46-3
Purity:  99.86%
Target:  

Bcl-2 Family

Research Areas:  

Cancer

MCL-1/BCL-2-IN-2 (Compound Nap-1) is a potent and selective Mcl-1 and Bcl-2 dual inhibitor with IC50s of 4.45 and 3.18 μM, respectively .
loading...
    loading...
Cat. No.: HY-116054
CAS No.: 1314096-68-8
Ibulocydine is an isobutyrate prodrug of the Cdk inhibitor BMK-Y101 (HY-188159), with oral activity, and exhibits IC50 values of approximately 50 nM against CDK1/CDK2, 530 nM against CDK7/cyclin H/Mat1, and 85 nM against CDK9/cyclin T. Ibulocydine reduces the phosphorylation levels of Rb, nucleolin, and RNA polymerase II CTD Ser-5 and Ser-2, downregulates the expression of Mcl-1, survivin, and XIAP, decreases MMP-9 expression, and lowers the Bcl-2/Bax ratio, activates calpain-mediated Bax cleavage, cytochrome c release, and caspase activation. Ibulocydine induces apoptosis, inhibits the growth of cancer cells and xenografts, enhances the sensitivity of cancer cells to TRAIL and radiotherapy, and blocks cancer cell metastasis. Ibulocydine can be used in research related to various cancers, including hepatocellular carcinoma, triple-negative breast cancer, lung cancer, and colon cancer .
loading...
    loading...